Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03581825 · ClinicalTrials.gov registry record · NA
Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population
A NA study, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
NCT03581825: Completed NA study, sponsored by Johnson & Johnson Vision Care.
NCT03581825 is a NA study that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 63 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03581825, a NA study, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a single-masked, randomized-controlled, dispensing clinical trial. A total of approximately 60 eligible myopic subjects will be targeted to complete the study.
Primary Outcome
Overall vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/pos
Interventions
- DEVICE senofilcon A Multifocal
- DEVICE senofilcon A Sphere
- DEVICE etafilcon A Multifocal
- DEVICE etafilcon A Sphere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-06-08 |
| Est. Completion | 2018-08-20 |
| Phase | NA |
What the finished NCT03581825 record still lists
NCT03581825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which senofilcon A Multifocal is the first listed.
NCT03581825 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03581825 about?
NCT03581825 is a clinical study titled "Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population". This is a single-masked, randomized-controlled, dispensing clinical trial. A total of approximately 60 eligible myopic subjects will be targeted to complete the study.
What is the current status of trial NCT03581825?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2018-06-08. Estimated completion is 2018-08-20.
What interventions are being tested in trial NCT03581825?
The interventions under investigation include: senofilcon A Multifocal (DEVICE), senofilcon A Sphere (DEVICE), etafilcon A Multifocal (DEVICE), etafilcon A Sphere (DEVICE).
Who is sponsoring clinical trial NCT03581825?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03581825's enrollment target sits among peer trials
63 1157th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI